CD138 Immunophenotyping by Flow Cytometry Test
Comprehensive Diagnostic Analysis for Plasma Cell Disorders
The CD138 Immunophenotyping by Flow Cytometry test represents a cutting-edge diagnostic approach for evaluating plasma cell disorders, particularly multiple myeloma. This sophisticated laboratory technique combines the precision of immunophenotyping with the analytical power of flow cytometry to provide detailed characterization of plasma cells expressing the CD138 surface antigen.
What is CD138 Immunophenotyping?
CD138, also known as syndecan-1, is a transmembrane heparan sulfate proteoglycan that serves as a specific marker for plasma cells. Immunophenotyping by flow cytometry enables the identification and quantification of cells expressing this antigen, providing crucial information about plasma cell populations in bone marrow and peripheral blood samples. This test is essential for distinguishing normal plasma cells from their malignant counterparts in multiple myeloma and related conditions.
What Does This Test Measure and Detect?
The CD138 Immunophenotyping test provides comprehensive analysis of several critical parameters:
- CD138 Expression Levels: Quantifies the presence and intensity of CD138 antigen on cell surfaces
- Plasma Cell Identification: Precisely identifies and characterizes plasma cell populations
- Abnormal Cell Detection: Detects malignant plasma cells with abnormal immunophenotypic patterns
- Disease Monitoring: Tracks changes in plasma cell populations over time
- Treatment Response Assessment: Evaluates how plasma cells respond to therapeutic interventions
Who Should Consider This Test?
This specialized diagnostic test is recommended for individuals presenting with symptoms or clinical findings suggestive of plasma cell disorders:
Clinical Indications
- Unexplained bone pain, particularly in the back or ribs
- Spontaneous fractures without significant trauma
- Persistent anemia that doesn’t respond to standard treatments
- Elevated serum protein levels or abnormal protein electrophoresis
- Kidney dysfunction with proteinuria
- Hypercalcemia without apparent cause
- Patients with established multiple myeloma requiring disease monitoring
- Individuals with monoclonal gammopathy of undetermined significance (MGUS)
Benefits of CD138 Immunophenotyping Testing
Early and Accurate Diagnosis
This test provides exceptional sensitivity in detecting early plasma cell malignancies, enabling timely intervention and improved treatment outcomes. The precise identification of CD138-positive cells allows for accurate differentiation between benign and malignant plasma cell populations.
Comprehensive Disease Monitoring
Regular testing facilitates ongoing assessment of disease progression and treatment effectiveness. The quantitative nature of flow cytometry provides objective data that helps clinicians make informed decisions about therapy adjustments and management strategies.
Personalized Treatment Planning
The detailed immunophenotypic profile obtained through this test supports the development of targeted treatment approaches. Understanding the specific characteristics of plasma cell populations enables more precise therapeutic interventions and better patient outcomes.
Understanding Your Test Results
Normal Findings
Normal results typically show a small population of CD138-positive plasma cells with characteristic immunophenotypic patterns. These cells should demonstrate polyclonal light chain expression and normal antigen density.
Abnormal Results Interpretation
Abnormal findings may include:
- Increased percentage of CD138-positive cells
- Abnormal immunophenotypic patterns suggesting clonality
- Presence of aberrant antigen expression
- Restricted light chain expression indicating monoclonal proliferation
Your hematologist or oncologist will interpret these results in the context of your clinical presentation, laboratory findings, and imaging studies to provide a comprehensive diagnosis and treatment plan.
Test Pricing and Availability
| Test Description | Price (USD) |
|---|---|
| Immunophenotyping by Flow Cytometry CD138 Test – Discount Price | $88 |
| Immunophenotyping by Flow Cytometry CD138 Test – Regular Price | $112 |
Sample Requirements and Turnaround Time
Turnaround Time: Sample Daily by 9 AM; Report Same Day
Sample Type: 3 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube AND 3 mL (2 mL min.) whole blood in 1 Green Top (Sodium Heparin) tube OR 2 mL (1 mL min.) Bone marrow in 1 Green Top (Sodium heparin) tube. Ship immediately at 18-22°C. DO NOT REFRIGERATE OR FREEZE. Specify time, date and clinical details on test request form.
Nationwide Testing Availability
We have comprehensive testing facilities across the United States, with branches in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our network ensures convenient access to this specialized testing regardless of your location.
Book Your CD138 Immunophenotyping Test Today
Take the first step toward comprehensive plasma cell disorder evaluation. Our experienced hematology specialists are ready to provide you with accurate, timely results and expert interpretation. Schedule your test today to benefit from our current promotional pricing and same-day reporting.
Call or WhatsApp: +1(267) 388-9828
Our dedicated patient care team is available to answer your questions, assist with scheduling, and provide guidance on sample collection and transportation requirements. Trust General Genetics Corporation for advanced diagnostic testing that puts your health first.
